Patent · US Expired

Method of using secretin for treating autism

US6197746A · kind A · utility

76Cited by
12References
12Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJan 13, 1999
Grant dateMar 6, 2001
Priority date
Expiry dateJan 13, 2019

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2800/38
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Secretin and secretin compositions are used for the treatment of autism and other neurological, behavioral and immunological disorders. The method includes administering an effective amount of secretin, such as Secretin-Ferring, to a patient. In one example, 2 clinical units (CU) of Secretin-Ferring was dissolved in a 7.5 ml solution of sodium chloride and was intravenously injected over 1 minute. In another example, secretin was administered transdermally by applying dimethyl sulfoxide (DMSO) to the patients skin and rubbing about 15 CU of Secretin-Ferring into the DMSO. Other methods and compositions for administering the effective amount of secretin include other transdermal carrier substances, such as gels, lotions, or patches; oral carriers, such as tablets, capsules, or lozenges; inhalation through the nose or mouth (e.g., as an aerosol); suppository forms of secretin and secretin compositions; and using acoustic waves to cause the secretin to penetrate the skin.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.